Development and evaluation of a formalin-inactivated West Nile Virus vaccine (WN-VAX) for a human vaccine candidate

Vaccine. 2010 Nov 23;28(50):7939-46. doi: 10.1016/j.vaccine.2010.09.076. Epub 2010 Oct 8.

Abstract

A formalin-inactivated West Nile Virus (WNV) vaccine (WN-VAX) derived from the WNV-NY99 strain was tested for its safety, efficacy, dilution limit for complete protection, and cross-neutralization. Safety tests performed with experimental animals, bacteria, or cultured cell lines showed no evidence of short- or long-term adverse effects. WN-VAX also protected 100% of 4-week-old mice against a lethal challenge from the WNV-NY99 strain after two doses of intraperitoneal inoculation-even when the vaccine was diluted to 3.2ng/dose. Moreover, very limited cross-neutralization activity against Japanese encephalitis virus, Dengue virus, Murray Valley encephalitis virus, Yellow fever virus or St. Louis encephalitis virus was observed. Therefore, the WN-VAX satisfies the requirements for human trials planned to be done in Japan.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line
  • Chlorocebus aethiops
  • Cross Protection*
  • Dogs
  • Female
  • Formaldehyde / pharmacology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mutagenicity Tests
  • Neutralization Tests
  • Rabbits
  • Rats
  • Toxicity Tests
  • Vaccines, Inactivated / immunology
  • Vero Cells
  • West Nile Fever / prevention & control*
  • West Nile Virus Vaccines / administration & dosage
  • West Nile Virus Vaccines / immunology*

Substances

  • Vaccines, Inactivated
  • West Nile Virus Vaccines
  • Formaldehyde